Curanex Pharmaceuticals Inc (CURX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CURX SEC filings page.
This page shows Curanex Pharmaceuticals Inc (CURX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Curanex is funding a larger research program through financing, while cash outflows exceed reported losses and revenue remains unreported.
The key change is not simply a bigger loss: in FY2025, operating cash outflow of$10.5M was about 2.5x the net loss of$4.2M , while financing supplied$15.3M . Accounting results therefore understate the cash required by reported activity.
R&D became the largest disclosed operating cost in FY2025 at
Total assets expanded from
Financial Health Signals
Curanex Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Curanex Pharmaceuticals Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Curanex Pharmaceuticals Inc reported a net loss of $4.2M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Curanex Pharmaceuticals Inc reported an operating loss of $4.2M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Curanex Pharmaceuticals Inc reported -$3.3M in net income in Q2 2026. This represents a decrease of 5353.5% from the same quarter a year earlier. Against the prior quarter it is down 4.5%.
Curanex Pharmaceuticals Inc earned -$0.12 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 9.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Curanex Pharmaceuticals Inc held $2.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Curanex Pharmaceuticals Inc's ROE was -68.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 49.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 29.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Curanex Pharmaceuticals Inc invested $2.6M in research and development in Q2 2026. Against the prior quarter it is up 15.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CURX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.6M | $2.3M | N/A | $677K | N/A | N/A | N/A | N/A |
| SG&A Expenses | $732K+1169.3% | $927K+574.6% | N/A | $274K+193.5% | $58K+30.4% | $137K | N/A | $93K |
| Operating Income | -$3.3M-5667.7% | -$3.2M-2216.0% | N/A | -$951K-919.7% | -$58K-30.4% | -$137K | N/A | -$93K |
| Interest Expense | N/A | N/A | N/A | $4K | $3K | $1K | N/A | N/A |
| Net Income | -$3.3M-5353.5% | -$3.2M-2189.7% | N/A | -$954K-946.5% | -$60K-36.5% | -$138K-71.5% | N/A | -$91K |
| EPS (Basic) | -$0.12 | -$0.11-1000.0% | -$0.12-700.0% | -$0.040.0% | $0.00+100.0% | -$0.01 | $0.02 | -$0.04 |
| EPS (Diluted) | -$0.12 | -$0.11 | -$0.12-700.0% | -$0.04 | $0.00+100.0% | -$0.01 | $0.02 | -$0.04 |
| Diluted Shares (Avg) | 28M+18.2% | 28M | N/A | 26M | 24M+900.0% | 24M | N/A | 2M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
CURX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.1M+544.6% | $8.4M | $11.6M+2135.8% | $14.5M | $787K | N/A | $518K | N/A |
| Current Assets | $4.8M+573.8% | $8.1M | $11.2M+2067.7% | $14.4M | $711K | N/A | $518K | N/A |
| Cash & Equivalents | $2.9M+2599.3% | $4.0M | $5.0M+3258.2% | $5.8M | $109K | N/A | $149K | N/A |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | N/A | $0 | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | N/A | $0 | N/A |
| Total Liabilities | $286K-40.6% | $333K | $361K+2377.1% | $186K | $482K | N/A | $15K | N/A |
| Current Liabilities | $104K+37.4% | $129K | $137K+840.2% | $186K | $76K | N/A | $15K | N/A |
| Non-Current Liabilities | $182K-55.2% | $204K | $224K | $0 | $406K | N/A | $0 | N/A |
| Total Equity | $4.8M+1467.5% | $8.1M+2108.6% | $11.2M+2128.8% | $14.3M+2189.8% | $305K-57.3% | $366K+181.6% | $503K | $624K |
| Retained Earnings | -$11.3M-1276.0% | -$8.0M | -$4.8M-678.8% | -$1.8M | -$820K | N/A | -$622K | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CURX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
CURX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -68.7%-49.0pp | -39.0%-1.4pp | N/A | -6.7%+7.9pp | -19.8%-13.6pp | -37.6%+24.1pp | N/A | -14.6% |
| Return on Assets | -64.9%-57.2pp | -37.5% | N/A | -6.6% | -7.7% | N/A | N/A | N/A |
| Current Ratio | 45.95+36.6x | 62.87 | 81.93+46.4x | 77.53 | 9.37 | N/A | 35.54 | N/A |
| Debt-to-Equity | 0.06-1.5x | 0.04 | 0.030.0x | 0.01 | 1.58 | N/A | 0.03 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc CURX | FY2025 | N/A | -$4.2M | N/A | $7.8M | — |
| Humacyte, Inc. HUMA | FY2025 | $2.0M | -$40.8M | N/A | $144.9M | 34/100 |
| Silence Therapeutics Plc SLN | FY2025 | $559K | -$88.6M | N/A | $661.3M | — |
| OmniAb, Inc. OABI | FY2025 | $18.7M | -$64.8M | N/A | $708.1M | 42/100 |
Where Curanex Pharmaceuticals Inc Ranks
Frequently Asked Questions
Is Curanex Pharmaceuticals Inc profitable?
No, Curanex Pharmaceuticals Inc (CURX) reported a net income of -$4.2M in fiscal year 2025.
What is Curanex Pharmaceuticals Inc's return on equity (ROE)?
Curanex Pharmaceuticals Inc (CURX) has a return on equity of -37.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Curanex Pharmaceuticals Inc's operating cash flow?
Curanex Pharmaceuticals Inc (CURX) recorded an outflow of $10.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Curanex Pharmaceuticals Inc's total assets?
Curanex Pharmaceuticals Inc (CURX) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Curanex Pharmaceuticals Inc spend on research and development?
Curanex Pharmaceuticals Inc (CURX) invested $3.0M in research and development during fiscal year 2025.
What is Curanex Pharmaceuticals Inc's current ratio?
Curanex Pharmaceuticals Inc (CURX) had a current ratio of 81.93 as of fiscal year 2025, which is generally considered healthy.
What is Curanex Pharmaceuticals Inc's debt-to-equity ratio?
Curanex Pharmaceuticals Inc (CURX) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Curanex Pharmaceuticals Inc's return on assets (ROA)?
Curanex Pharmaceuticals Inc (CURX) had a return on assets of -36.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Curanex Pharmaceuticals Inc's P/E ratio?
Curanex Pharmaceuticals Inc (CURX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.8M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Curanex Pharmaceuticals Inc's price-to-sales ratio?
Curanex Pharmaceuticals Inc (CURX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.8M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Curanex Pharmaceuticals Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Curanex Pharmaceuticals Inc (CURX) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.5M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Curanex Pharmaceuticals Inc's Piotroski F-Score?
Curanex Pharmaceuticals Inc (CURX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Curanex Pharmaceuticals Inc's earnings high quality?
Curanex Pharmaceuticals Inc (CURX) reported a net loss of $4.2M while operations used $10.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Curanex Pharmaceuticals Inc cover its interest payments?
Curanex Pharmaceuticals Inc (CURX) reported an operating loss of $4.2M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.